As we know, TP53, KRAS, and BRAF mutation status are related to the sensitivity of chemotherapy and immunotherapy, as well as can be used as a prognostic marker in CRC (Carethers and Jung, 2015). Here, KRAS is linked to colorectal carcinoma.